Resveratrol (Resv), a natural occurring phytolexin present in grapes and other foods, possesses chemopreventive effects revealed by its striking modulation of diverse cellular events associated with tumor initiation, promotion and progression. Catechol estrogens generated in the metabolism of estrogens are oxidized to catechol quinones that react with DNA to form predominantly depurinating estrogen-DNA adducts. This event can generate the mutations responsible for cancer initiation. In this regard, Resv acts as both an antioxidant and an inducer of the phase II enzyme NAD (P)H:quinone oxidoreductase 1 (NQO1). In this report, we present the effects of Resv on the metabolism of estrogens in normal breast epithelial cells (MCF-10F) treated with 4-hydroxyestradiol (4-OHE 2 ) or estradiol-3,4-quinone (E 2 -3,4-Q). Resv induced NQO1 in a dose-and time-dependent manner, but did not affect the expression of catechol-O-methyltransferase. Ultraperformance liquid chromatography/tandem mass spectrometry was used to determine the effects of Resv on estrogen metabolism. Preincubation of the cells with Resv for 48 h decreased the formation of depurinating estrogen-DNA adducts from 4-OHE 2 or E 2 -3,4-Q and increased formation of methoxycatechol estrogens. When Resv was also present with the 4-OHE 2 or E 2 -3,4-Q, even greater increases in methoxycatechol estrogens were observed, and the DNA adducts were undetectable. We conclude that Resv can protect breast cells from carcinogenic estrogen metabolites, suggesting that it could be used in breast cancer prevention.
Introduction
Resveratrol (3, 5, Resv) , which is present in red wine and grapes, has been widely studied for its antioxidant and biological effects [1] . It has been shown to induce anticancer effects by modulating several cellular pathways related to cancer initiation, promotion and progression [2] [3] [4] . Resv inhibits cell proliferation and induces apoptosis to suppress and prevent a variety of tumors [5] . Resv stops the proliferation of human breast cancer MCF-7 cells and non-transformed MCF-10F cells treated with estrogens [6] [7] [8] . The molecular mechanisms underlying these activities are not completely understood.
Estrogens are metabolized to catechol estrogens and then to catechol estrogen quinones, which can act as endogenous carcinogens [9] [10] [11] [12] (Figure 1 ). These quinones react with DNA to form predominantly the depurinating 4-hydroxyestrone(estradiol) [OHE 1 (E 2 )-1-N3Ade] and 4-OHE 1 (E 2 )-1-N7Gua adducts [9] [10] [11] [12] [13] . Error-prone repair of the abasic sites left in the DNA by the depurination is thought to generate the mutations that are critical for cell proliferation and cancer initiation [14] [15] [16] . Low catechol-O-methyltransferase (COMT) activity and increased formation of DNA adducts mediated through the catechol estrogen quinones may be contributory factors in the initiation of breast cancer [17, 18] . In fact, Gaikwad et. al. have shown that in healthy women the levels of estrogen-DNA adducts in urine are low and the levels of methoxylated estrogen metabolites and conjugates are high [11] . In contrast, higher levels of DNA adducts and lower levels of methoxylated estrogen metabolites and conjugates are present in the urine of high-risk women and women with breast cancer. Based on this information, it could be argued that lowering the depurinating DNA adduct levels may lead to reduction in the risk of developing breast cancer. This could be achieved by methylation of 4-OHE 1 (E 2 ) by COMT, reduction of estrogen quinones by quinone oxidoreductase 1 or 2 (NQO1 or NQO2 [19, 20] ), reduction of estrogen semiquinones by an antioxidant [21, 22] and/or conjugation of estrogen quinones with glutathione or derivatives [9, 11] . In a preliminary in vitro study, we tested the ability of four antioxidant dietary supplements, N-acetylcysteine, Resv, melatonin and reduced lipoic acid to inhibit formation of estrogen-DNA adducts [22] . Resv inhibited best the formation of depurinating adducts when enzyme-oxidized 4-OHE 2 was reacted with DNA. Only the antioxidant effects of Resv, presumably the reduction of E 2 -3,4-semiquinone to 4-OHE 2 , were evaluated in this study. The in vivo preventive effects of Resv are a combination of its antioxidant properties and its ability to induce NQO1 [23, 24] and modulate CYP1B1 [24, 25] (Figure 1 ).
The effects of Resv on the metabolism of estrogens in general, and on the formation of depurinating DNA adducts in particular, have never been investigated. In this article we show that Resv, indeed, completely inhibits estrogen-DNA adduct formation in human breast epithelial cells (MCF-10F) through its antioxidant properties, as well as induction of the phase II enzyme NQO1. This study is the first report on the metabolism of E 2 -3,4-Q and 4-OHE 2 by MCF-10F cells in the presence of Resv, and it provides evidence that Resv may be a new hope for prevention of breast cancer. 2 and all standards were synthesized in our laboratory, as previously described [26] [27] [28] [29] . For quinone treatments, the E 2 -3,4-Q was freshly synthesized as previously described [10] . Resv and all other chemicals were purchased from Sigma (St. Louis, MO).
Materials and Methods

Chemicals and Reagents
4-OHE
Cell culture and treatment
MCF-10F cells were obtained from the ATCC (Rockville, MD) and cultured in DMEM and Ham's F12 media (Mediatech, Inc.) with 20 ng/ml epidermal growth factor, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone, 5% horse serum and 100 μg/ml penicillin/streptomycin mixture. Estrogen-free medium was prepared in phenol red-free DME/F12 medium with charcoalstripped FBS (HyClone, Logan, UT). Cell viability was determined by the MTT [3,(4,5-dimethylthiazole-2-yl)-2,5-diphenyltrazolium bromide] assay [30] .
The MCF-10F cells (0.75 × 10 5 cells) were seeded for 48 h in estrogen-containing medium. The medium was changed to estrogen-free medium and the cells were grown for another 72 h. To see the effect of Resv on NQO1 and COMT induction, cells were first pre-incubated for 48 h with 25 μM Resv, washed with PBS and, after adding fresh medium, treated with E 2 -3,4-Q or 4-OHE 2 (1, 10 or 30 μM) for 24 h. To check the combined induction and antioxidant effects, cells were pre-incubated with 25 μM Resv for 48 h and then again with fresh 25 μM Resv after changing medium and while treating with 4-OHE 2 or E 2 -3,4-Q (1, 10 or 30 μM).
To examine the dose-dependency of the Resv effects, cells were treated with 1, 10 or 30 μM Resv, while keeping the 4-OHE 2 constant at 10 μM. To keep the concentration of DMSO (0.001%) the same in all experiments, different stock solutions of 4-OHE 2 (1-30 mM) and Resv (0.1-30 mM) were prepared. Media from four T-150 flasks of MCF-10F cells treated with an equal amount of organic solvent were used as controls.
Analysis of estrogen-DNA adducts
Following the treatments, the media were harvested, supplemented with 2 mM ascorbic acid (to prevent possible decomposition of the compounds) and processed immediately. Sample preparation and analysis by ultraperformance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) were carried out as follows:
i. Sample preparation-Culture media from four flasks (40 mL) were processed by passing through Varian C8 Certify II cartridges (Varian, Harbor City, CA). The cartridges were preequilibrated by sequentially passing 1 ml of methanol, distilled water, and potassium phosphate buffer (100 mM, pH 8) through them. Culture media were adjusted with 1 ml of 1 M potassium phosphate buffer to pH 8.0 and passed through the cartridges. After washing with 200 μl of the phosphate buffer, the analytes were eluted with 1 ml of elution buffer [methanol:acetonitrile:water: trifluoroacetic acid (8:1:1:0.1)] and processed as previously described [18] .
ii. UPLC-MS/MS-Samples were analyzed on an Acquity UPLC system connected to a MicroMass QuattroMicro triple quadrupole mass spectrometer (Waters, Milford, MA) [11] . The 10-μl injections were carried out on a Waters Acquity UPLC BEHC 18 column (1.7 μm, 1 × 100 mm). The instrument was operated in the positive electrospray ionization mode. All aspects of system operation, data acquisition and processing were controlled using QuanLynx v4.0 software (Waters). The column was eluted starting with 5% acetonitrile in water (0.1% formic acid) for 1 min at a flow rate of 150 μl/min; then a gradient to 55% acetonitrile in 10 min was run. Ionization was achieved using the following settings: capillary voltage 3 kV; cone voltage 15-40 V; source block temperature 100 °C; desolvation temperature 200 °C, with a nitrogen flow of 400 l/h. Nitrogen was used as both the desolvation and auxiliary gas. Argon was used as the collision gas. Three-point calibration curves were run for each standard. Triplicate samples were analyzed for each data point.
The UPLC-MS/MS limit of detection for the estrogen derivatives was in the range of 0.002 to 0.06 pmole, which was well below the experimental values obtained for all the compounds, and the standard error for this analysis, calculated from triplicate analyses was 0.00002-0.0066 pmole. 
UPLC-MS/MS
Immunoblotting
Comprehensive analysis of the expression patterns of the protective phase II enzymes (COMT and NQO1) from control and treated MCF-10F cells at different time points was conducted by immunoblotting. Whole cell lysates were prepared by suspending cells in RIPA buffer with protease inhibitor and lysed by three freeze-thaw cycles. After removing cellular debris by centrifugation, protein concentrations were determined by using a BCA protein assay kit (Pierce Biotechnology, Rockford, IL). The proteins were separated by SDS-PAGE and transferred to PVD membranes for immunodetection as previously described [17] . Dilutions of the primary anti-COMT (Chemicon International, Temecula, CA) and NQO1 (Abcam, Temecula, CA) antibodies were made in blocking solution (5% non-fat dry milk in PBS). The blots were incubated for 3 h with primary antibody and for 1 h with secondary antibody coupled to horseradish peroxidase at room temperature. After each step, blots were washed with PBST (PBS and 0.1% Tween-20), incubated with ECL solution (Amersham Biotech, Piscataway, NJ) for 1 min, and visualized with radiographic film. The intensities of the bands were quantified by Alpha DigiDoc 1201 (Alpha Innotech, San Leandro, CA).
Determination of NQO1 activity by UPLC-MS/MS
Cellular NQO1 (25 μg of whole cell lysate protein) from control and 25 μM Resv-treated MCF-10F cells was prepared. Triplicate enzyme reactions were carried out in a final volume of 100 μl of 0.1 M sodium phosphate, pH 7. We used freshly synthesized E 2 -3,4-Q as the substrate and 25 μM NADH as the co-factor in the buffer system containing 0.7 mg/ml BSA. Recombinant NQO1 protein (10 units, Sigma, St. Louis, MO) in the reaction system served as the positive control. Inhibition studies were carried out with inclusion of a potent inhibitor of NQO1, dicumarol (10 μM), in the assay mixture. Control assays were carried out without enzyme or cofactor. The reaction mixture was pre-incubated for 3 min at room temperature prior to the addition of substrate. The reaction was then initiated by adding 5 μl of 100 μM E 2 -3,4-Q in acetonitrile and terminated after 27 min at 37 °C by adding 100 μl methanol. Following centrifugation to precipitate proteins, the supernatant was passed through a 5,000 M.W. cut-off filter (Millipore, Billerica, MA), and 100 μl of each sample was analyzed for the product, 4-OHE 2 , by UPLC-MS/MS.
Determination of COMT activity by UPLC-MS/MS
Cellular COMT from control and 25 μM Resv (0-72 h)-treated MCF-10F cells was prepared as a cytosolic extract. Enzyme reactions were carried out in a final volume of 250 μl of 0.1 M sodium phosphate, pH 7.8, containing 1 mM DTT, 5 mM MgCl 2 , 100 μg cytosolic protein, 100 μM 4-OHE 2 , and 200 μM S-adenosylmethionine (SAM, saturating). The incubation mixture, except for the substrate, was pre-incubated for 3 min at 37 °C. Then, the reaction was initiated by adding 5 μl of 4-OHE 2 in DMSO and terminated after 27 min by adding 25 μl of 4 M perchloric acid. Following centrifugation to precipitate proteins, the supernatant (245 μl) was passed through a 5,000 M.W. cut-off filter (Millipore, Billerica, MA), and 10 μl of each sample was analyzed by UPLC-MS/MS. Each analysis was conducted in triplicate.
Statistical Analysis
The statistical significance of the results was determined by Student's t-test and ANOVA analysis by using SAS and GraphPad Prism 4.0 software. P<0.05 was considered significant. All data were obtained from triplicate experiments.
Results
Effect of Resv on NQO1 and COMT expression and activity
To see the effect of Resv on NQO1, MCF-10F cells were treated with various concentrations of Resv (0-50 μM) for 48 h and the level of NQO1 protein was determined by immunoblotting. Densitometric analyses showed that Resv dose-and time-dependently induced the expression of NQO1 (Figure 3) . Resv (0-50 μM) induced NQO1 protein 2-3 fold ( Figure 3A) . A time course study using 25 μM Resv for 24-72 h demonstrated that induction of NQO1 protein occurred by 24 h and peaked at 48 h, while its level fell slightly by 72 h ( Figure 3B) . Treatment of the cells with 25 μM Resv 2 or 3 times for 24 h each time or for 48 h + 24 h, resulted in approximately the same amount of NQO1 protein ( Figure 3B ). The catalytic activity of cellular NQO1 in control and Resv-treated cells was determined by an in vitro enzyme activity assay using UPLC-MS/MS. The levels of the reaction product, 4-OHE 2 , in treated cells were significantly greater than in the untreated cells (p< 0.05), as determined by ANOVA ( Figure  3C ). The level of 4-OHE 2 in reaction mixtures containing recombinant NQO1 protein, the positive control, was 78.5±11.5 pg/μl, whereas the cellular proteins from 25 μM Resv-treated cells showed a 2-fold increase in enzymatic activity compared with that from control cells (4-OHE 2 = 123±10.3 pg/μl). The reduction of E 2 -3,4-Q to 4-OHE 2 by NQO1 was subsequently confirmed by adding its potent inhibitor dicumarol (10 μM) to the assay mixture, which almost completely inhibited the formation of 4-OHE 2 . Control assays carried out without enzyme or cofactor had lower levels of 4-OHE 2 (4.3±1.2 pg/μl). In the presence of NADH, the level was slightly higher, 16.7 ± 5.7 pg/μl. The increased NQO1 activity in Resv-treated cells corresponded well with the induction in NQO1 protein.
Although the levels of methoxy catechol estrogens increased in the culture medium when Resv was present, it did not change the COMT protein level in a time-or dose-dependent manner ( Figure 4A and 4B) . To investigate the activity of COMT in Resv-treated and untreated MCF-10F cells, and to validate the findings from our immunoblotting experiments, catalytic activity was measured by LC/MS using 4-OHE 2 as the substrate ( Figure 4C ). No change in COMT activity was observed. This is not consistent with earlier reports in which COMT enzyme levels were not changed, but catalytic activity was affected [31] .
Taken together, our results clearly demonstrate that Resv induces NQO1 protein in a time and dose dependent manner, whereas COMT protein and activity remain unaffected.
Treatment of cells
MCF-10F cell treatments with either 4-OHE 2 or E 2 -3,4-Q were divided into three groups. First, the control group was treated for 24 h with 4-OHE 2 or E 2 -3,4-Q alone. In the second group, to ascertain the contribution of induced NQO1, cells were pretreated with 25 μM Resv for 48 h, followed by 4-OHE 2 or E 2 -3,4-Q for 24 h. In the third group, pretreatment with 25 μM Resv was followed by treatment with 4-OHE 2 or E 2 -3,4-Q plus fresh 25 μM Resv to determine its antioxidant effect.
Effect of Resv on 4-OHE 2 metabolism in MCF-10F cells
UPLC-MS/MS analysis of the cell culture media from the control group, which was treated with 1, 10 or 30 μM 4-OHE 2 , showed that 4-OHE 2 is predominantly metabolized to 4-methoxycatechol estrogens, with small amounts of thiol conjugates and depurinating estrogen-DNA adducts in a dose-dependent manner (Table 1, Figure 5 ). Both adducts were present in the media at concentrations ranging from 10 pM to 470 pM, depending on the concentration of 4-OHE 2 used to treat the cells.
When the MCF-10F cells were preincubated with Resv, a significant increase in 4-OCH 3 E 1 (E 2 ) (~ 1.5-fold) was observed (Table 1, Figure 5A ). When preincubation with Resv was followed by incubation with both 4-OHE 2 and Resv, the level of 4-OCH 3 E 1 (E 2 ) was further increased (Table 1, Figure 5A ). The level obtained with Resv preincubation is compatible with oxidation of 4-OHE 2 to quinone and subsequent reduction of the quinone back to catechol, catalyzed by Resv-induced NQO1. The enhancement in 4-OCH 3 E 1 (E 2 ) when Resv is included with 4-OHE 2 is interpreted as the reduction of E 1 (E 2 )-3,4-semiquinone back to catechol, with subsequent COMT-catalyzed methylation (Figures 1 and 5A ).
The levels of GSH, Cys and NAcCys conjugates remained low under all three sets of experimental conditions (Table 1 ). The levels of the two depurinating DNA adducts were decreased when the cells were preincubated with Resv and became undetectable when the cells were preincubated with Resv and incubated with 4-OHE 2 plus Resv (Table 1, Figure 5B ).
Effect of Resv on E 2 -3,4-Q metabolism in MCF-10F cells
Much lower levels of 4-OCH 3 E 1 (E 2 ) were observed when the MCF-10F cells were incubated with E 2 -3,4-Q (Table 2 ) compared to 4-OHE 2 (Table 1) . When the cells were preincubated with Resv, the level of 4-OCH 3 E 1 (E 2 ) increased about 30%, and inclusion of Resv with E 2 -3,4-Q led to a doubling of the levels of 4-OCH 3 E 1 (E 2 ) (Table 2, Figure 6A ). The levels of thiol conjugates showed a small dose-response, but were unaffected by preincubation or incubation with Resv ( Table 2 ). The levels of the depurinating DNA adducts were lower with E 2 -3,4-Q than with 4-OHE 2 (Table 1) , and they decreased dramatically with Resv preincubation, once again becoming undetectable when the cells were preincubated with Resv and incubated with E 2 -3,4-Q + Resv (Table 2, Figure 6B ).
Dose-Response of Resv
MCF-10F cells were treated with 10 μM 4-OHE 2 and varying concentrations (0, 1, 10, 30 μM) of Resv, and the metabolic profile was analyzed by UPLC-MS/MS. There was a dosedependent increase in the level of 4-methoxycatechol estrogens, with a small increase at equimolar 4-OHE 2 and Resv and a 3-fold increase when the concentration of Resv was 3-times that of 4-OHE 2 (Table 3 ). There was a marginal, dose-dependent decrease in the corresponding levels of the 4-OHE 1 (E 2 )-2-SG, 4-OHE 1 (E 2 )-2-Cys and 4-OHE 1 (E 2 )-2-NAcCys conjugates compared with control (Table 3 ). Significant inhibition of 4-OHE 1 (E 2 )-1-N3Ade and 4-OHE 1 (E 2 )-1-N7Gua adduct formation was observed with increased Resv concentrations and the adducts were not detected with 30 μM Resv (Table 3) .
Discussion
Resv induced NQO1 protein and activity in MCF-10F cells in a dose-and time-dependent manner, with maximal induction after 48 h (Figure 3) . The induction of NQO1 by Resv occurs through transcriptional events [24, 32, 33] and is accompanied by localization of NQO1 in the nucleus [24] . When the cells were pre-incubated with Resv for 48 h, the effects of NQO1 induction on the metabolism of 4-OHE 2 can be observed from the increasing formation of 4-OCH 3 E 1 (E 2 ) and decreasing amounts of 4-OHE 1 (E 2 )-1-N3Ade and 4-OHE 1 (E 2 )-1-N7Gua adducts (Table 1, Figure 5 ). The level of methoxycatechol estrogens increased about 50% and the level of adducts decreased about 2-fold at all three doses of 4-OHE 2 . A similar effect of Resv was seen when the cells were incubated with E 2 -3,4-Q, following pre-incubation with Resv for 48 h (Table 2, Figure 6 ). In this case, the levels of 4-OCH 3 E 1 (E 2 ) were much lower than with 4-OHE 2 as the estrogen, but the increase in methoxycatechol estrogens across doses of E 2 -3,4-Q was about 30%, while the decrease in depurinating estrogen-DNA adducts was greater than 50% and they were no longer detectable at the lowest dose of the estrogen. Marginal changes were seen in the levels of thiol conjugates (Table 1) .
Pre-incubation with Resv had no effect on the expression of COMT as detected by its level of protein or catalytic activity (Figure 4) . The level of COMT in the MCF-10F cells was sufficiently high to methylate virtually all of the 4-OHE 1 (E 2 ) present in the cells incubated with either 4-OHE 2 or E 2 -3,4-Q (Tables 1 and 2 ).
To investigate the antioxidant effect of Resv, the MCF-10F cells were pre-incubated with Resv for 48 h, then the cells were incubated with 4-OHE 2 or E 2 -3,4-Q plus a second dose of Resv (Tables 1 and 2 , Figures 5 and 6 ). Little further induction of NQO1 during this 24 h period would be expected, based on the results shown in Figure 3 . Thus, the effects of Resv observed correspond to its antioxidant properties.
With 4-OHE 2 as the estrogen, the levels of 4-OCH 3 E 1 (E 2 ) were 2-2.5 times those seen with 4-OHE 2 alone, and no depurinating estrogen-DNA adducts could be detected (Table 1, Figure  5 ). The ratio of 4-OHE 2 to Resv affected the estrogen metabolism (Table 3 ). Little effect was observed when the concentration of Resv was 10% that of 4-OHE 2 ; at equimolar doses, the methoxycatechol estrogens increased about 30% and a similar decrease in adducts was seen. When the level of Resv was 3-times that of the catechol estrogen, however, the level of 4-OCH 3 E 1 (E 2 ) approximately tripled, and the adducts were not detected ( Table 3 ).
The antioxidant effect of Resv is due to the high energy of resonance of its one-electron oxidized form, namely, the 4′-oxyradical [34] . This chemical property can give Resv the capacity to reduce the E 2 -3,4-semiquinone to 4-OHE 2 , as already observed in vitro when enzyme-activated 4-OHE 2 was reacted with DNA [22] . This reduction has also been observed for cysteine and N-acetylcysteine [21, 22] . With E 2 -3,4-Q as the estrogen, the levels of methoxycatechol estrogens were almost twice those seen with the quinone alone, and the adducts were not detected (Table 2, Figure 6 ). Inclusion of Resv with E 2 -3,4-Q had little effect on the formation of thiol conjugates ( Table 2 ).
The ability of Resv to modulate estrogen metabolism may be important in the prevention of breast, prostate and other estrogen-initiated cancers. Men with prostate cancer [12] and women with breast cancer or at high risk for the disease [11] form significantly higher amounts of the depurinating estrogen-DNA adducts than healthy men or women. Thus, formation of these adducts appears to play a critical role in the initiation of these cancers [9, 11, 12] . The results reported here clearly show that Resv can induce NQO1, which serves as a protective enzyme, by reducing the amount of catechol estrogen quinones available to react with DNA and form depurinating adducts. In addition, Resv inhibits CYP1B1, which catalyzes the formation of 4-OHE 1 (E 2 ) [24, 25] .
In summary, the inhibitory effects of Resv are the sum of three factors. One is the induction of NQO1 that provides a decrease in estrogen quinones and an increase in catechol estrogen [24] . The second factor is the inhibition of CYP1B1 expression, which decreases the formation of 4-catechol estrogens [24, 25] . The third factor is the antioxidant properties of Resv that reduce the estrogen semiquinones to catechol estrogens, as indirectly determined in vitro [22] . Thus, Resv may be very effective in preventing cancer initiation by estrogens because it induces the protective enzyme NQO1, as reported here and in reference 24, it inhibits overexpression of CYP1B1 [24, 25] , and it acts as an antioxidant, presumably reducing catechol estrogen semiquinones to catechol estrogens [21, 22, 34] . Mechanisms by which Resv can prevent estrogen-initiated breast cancer. Incubation of MCF-10F cells with E 2 -3,4-Q with or without 25 μM 
